Build status - In Progress

A Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

A Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
Recruiting
18 years - 75 years
All
Phase 2
4 participants needed
1 Location

Brief description of study

The objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Pulmonary Arterial Hypertension,PAH
  • Age: 18 years - 75 years
  • Gender: All

Male and Female, Age 18-75, diagnosis of symptomatic PAH,(Pulmonary Arterial Hypertension)

Updated on 04 Aug 2024. Study ID: 848470

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center